Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 8,500 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $7.49, for a total transaction of $63,665.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Clay Thorp also recently made the following trade(s):

  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total transaction of $45,120.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total transaction of $184,240.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.98, for a total transaction of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.02, for a total transaction of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.57, for a total transaction of $185,465.00.

Shares of Clearside Biomedical, Inc. (CLSD) traded up 0.80% during mid-day trading on Friday, hitting $7.60. 224,557 shares of the stock traded hands. Clearside Biomedical, Inc. has a 12 month low of $6.50 and a 12 month high of $25.08. The company’s market cap is $192.55 million. The firm has a 50 day moving average of $7.68 and a 200 day moving average of $7.97.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.13). The business had revenue of $0.13 million for the quarter. Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. Equities analysts anticipate that Clearside Biomedical, Inc. will post ($2.10) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/16/clearside-biomedical-inc-clsd-director-clay-thorp-sells-8500-shares-of-stock.html.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in Clearside Biomedical by 31.6% during the first quarter. Wellington Management Group LLP now owns 2,164,703 shares of the company’s stock worth $17,187,000 after purchasing an additional 520,403 shares during the period. AWM Investment Company Inc. raised its stake in Clearside Biomedical by 173.0% during the first quarter. AWM Investment Company Inc. now owns 341,217 shares of the company’s stock worth $2,709,000 after purchasing an additional 216,217 shares during the period. Marshall Wace North America L.P. purchased a new position in Clearside Biomedical during the first quarter worth about $1,720,000. MARSHALL WACE ASIA Ltd purchased a new position in Clearside Biomedical during the first quarter worth about $1,720,000. Finally, State Street Corp raised its stake in Clearside Biomedical by 99.7% during the second quarter. State Street Corp now owns 259,599 shares of the company’s stock worth $2,367,000 after purchasing an additional 129,621 shares during the period. Hedge funds and other institutional investors own 52.45% of the company’s stock.

Several analysts have commented on CLSD shares. JMP Securities started coverage on shares of Clearside Biomedical in a research note on Thursday, May 25th. They issued an “outperform” rating and a $21.00 price target on the stock. Cowen and Company reiterated a “buy” rating on shares of Clearside Biomedical in a research note on Thursday, June 8th. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Zacks Investment Research upgraded shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Tuesday, July 11th. Finally, TheStreet cut shares of Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $19.00.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Stock Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related stocks with our FREE daily email newsletter.